23948sdkhjf
Logga in eller skapa en prenumeration för att spara artiklar
Få tillgång till allt innehåll på Medtech Magazine
Ingen bindningstid eller kortinformation krävs
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
Annons
Annons
Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Improved flexibility for CTIS submissions

A new “Article 11 workaround” is addressing a long-standing limitation in CTIS when working with Part I-only submissions in multi-country clinical trials.

Sponsors can now include Member States with only Part I in the initial submission by using placeholders for Part II—making it easier to:

•    Add new Member States
•    Submit substantial modifications
•    Avoid process bottlenecks

A practical step forward in making CTIS workflows more adaptable to real-world study needs. Read more about this workaround in the CTCG guidance from the Clinical Trials Coordination Group (CTCG). Learn more

At Aurevia, we’re seeing how small system changes like this can have a meaningful impact on planning and execution across multi-country trials.

Do you need support with your CTIS submissions? Our clinical trial experts can support your regulatory submissions during your entire clinical study, from start-up to close-out. 

Our clinical experience, flexibility, and strong local presence enable us to deliver support that keeps studies moving forward.

Contact us

 

Aurevia
Box 150 27
750 15 Uppsala
Uppsala kommun
Sverige
VAT nummer: SE5565873147

Kontaktperson

Ulrika Heldestad
BD & Sales Director, CRO
ulrika.heldestad@aurevia.com
Annons Annons
BREAKING
{{ article.headline }}
0.11|